Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immature Platelet Fraction as a Surrogate Marker of Thrombo-Inflammation in Hospitalized COVID-19 Patients.

Life (Basel, Switzerland)·2025
Same author

RVd and CyBorD therapies remodel B-cell maturation signaling and alter immune and clonal architecture in multiple myeloma.

Cancer biology & therapy·2025
Same author

STK405759 targets microtubules, modulates STAT1, and enhances ruxolitinib efficacy in myeloproliferative neoplasms.

American journal of cancer research·2025
Same author

CyTOF profiling of bone marrow immune dynamics across myeloma stages.

Oncoimmunology·2025
Same author

Report of Consensus Panel 1 from the 12th International Workshop on the management of patients with IgM and Waldenstrom's Macroglobulinemia related neuropathy.

Seminars in hematology·2025
Same author

Lymphoplasmacytic lymphoma and multiple myeloma coexisting in the same patient: a case series and literature review.

Leukemia & lymphoma·2024
Same journal

An Update on the Role of Renal Artery Denervation in the Treatment of Hypertension.

Current treatment options in cardiovascular medicine·2026
Same journal

Advancements and Challenges in Contemporizing Care for Adult Patients with Congenital Heart Disease and Advanced Heart Failure: An Update on Application of Modern Heart Failure Technologies.

Current treatment options in cardiovascular medicine·2026
Same journal

Evolving Decongestion Strategies in the Management of Acute Heart Failure.

Current treatment options in cardiovascular medicine·2025
Same journal

Advanced Electroanatomic Mapping: Current and Emerging Approaches.

Current treatment options in cardiovascular medicine·2025
Same journal

Metabolic Reprogramming in Heart Failure: From Energy Starvation to Therapeutic Targets.

Current treatment options in cardiovascular medicine·2025
Same journal

Drug-Coated Balloons for Coronary Artery Disease: From Theory to Practice.

Current treatment options in cardiovascular medicine·2025
See all related articles

Related Experiment Video

Updated: Jun 30, 2026

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

Behcet's Disease: Current Therapeutic Perspectives.

Merav Leiba1, Michael Ehrenfeld

  • 1Department of Medicine C, Sheba Medical Center, Tel-Hashomer Hospital & the Tel-Aviv University Faculty of Medicine,Tel Aviv52621,Israel. ehrenfel@post.tau.ac.il.

Current Treatment Options in Cardiovascular Medicine
|June 7, 2005
PubMed
Summary
This summary is machine-generated.

Behcet's disease, a systemic vasculitis, presents challenges in treatment. Emerging anti-tumor necrosis factor (TNF) therapies show promise in managing severe symptoms and preventing organ damage.

Related Experiment Videos

Last Updated: Jun 30, 2026

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

Area of Science:

  • Immunology
  • Rheumatology
  • Vascular Medicine

Background:

  • Behcet's disease is a chronic, relapsing systemic vasculitis with unknown causes.
  • It affects small and large blood vessels, leading to oral/genital ulcers and ocular inflammation.
  • Multisystemic involvement includes joints, skin, GI, pulmonary, renal, CNS, and cardiovascular systems.

Purpose of the Study:

  • To review current and emerging therapeutic strategies for Behcet's disease.
  • To evaluate the efficacy of various anti-inflammatory and immunosuppressive agents.
  • To highlight the potential of anti-tumor necrosis factor (TNF) therapies.

Main Methods:

  • Review of existing literature on Behcet's disease treatments.
  • Analysis of conventional immunosuppressive agents (colchicine, azathioprine, corticosteroids, etc.).
  • Evaluation of newer therapies including thalidomide, interferons, and anti-TNF agents.

Main Results:

  • Conventional therapies offer symptomatic control but are not universally effective.
  • Emerging treatments like thalidomide and interferons show efficacy.
  • Anti-TNF agents (e.g., infliximab) demonstrate rapid control of severe manifestations like panuveitis and cerebral vasculitis.

Conclusions:

  • Behcet's disease treatment remains largely empirical, aiming to control symptoms and prevent organ damage.
  • Anti-TNF therapy represents a significant advancement, particularly for sight-threatening and severe systemic involvement.
  • Ongoing clinical trials are crucial to further define the role of anti-TNF agents versus conventional immunosuppressants.